International Journal of Nanomedicine

Background It was recently reported that iron oxide nanoparticles attenuated antigen-specific humoral responses and T cell cytokine expression in ovalbumin-sensitized mice. It is presently unclear whether iron oxide nanoparticles influence T helper 1 cell-mediated immunity. The present study aimed to investigate the effect of iron oxide nanoparticles on delayed-type hypersensitivity (DTH), whose pathophysiology requires the participation of T helper 1 cells and macrophages. Methods DTH was elicited by a subcutaneous challenge with ovalbumin to the footpads of mice sensitized with ovalbumin. Iron oxide nanoparticles (0.2–10 mg iron/kg) were administered intravenously 1 hour prior to ovalbumin sensitization. Local inflammatory responses were examined by footpad swelling and histological analysis. The expression of cytokines by splenocytes was measured by enzyme-linked immunosorbent assay. Results Administration of iron oxide nanoparticles, in a dose-dependent fashion, significantly attenuated inflammatory reactions associated with DTH, including the footpad swelling, the infiltration of T cells and macrophages, and the expression of interferon-γ, interleukin-6, and tumor necrosis factor-α in the inflammatory site. Iron oxide nanoparticles also demonstrated a suppressive effect on ovalbumin-stimulated production of interferon-γ by splenocytes and the phagocytic activity of splenic CD11b+ cells. Conclusion These results demonstrated that a single dose of iron oxide nanoparticles attenuated DTH reactions by suppressing the infiltration and functional activity of T helper 1 cells and macrophages in response to antigen stimulation.

[1]  K. Takeda,et al.  Attenuation of delayed-type hypersensitivity by fullerene treatment. , 2009, Toxicology.

[2]  Peter van Gelderen,et al.  Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells , 2001, Nature Biotechnology.

[3]  W. Pegios,et al.  [The value of the liver-specific superparamagnetic contrast medium AMI-25 for the detection and differential diagnosis of primary liver tumors versus metastases]. , 1994, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[4]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[5]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[6]  Hon-Man Liu,et al.  Macrophage physiological function after superparamagnetic iron oxide labeling , 2008, NMR in biomedicine.

[7]  Chia-Chi Wang,et al.  A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression , 2011, International journal of nanomedicine.

[8]  K. Kaneda,et al.  Immunopathogenesis of delayed‐type hypersensitivity , 2001, Microscopy research and technique.

[9]  Q. Pankhurst,et al.  Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. , 2007, Biochimica et biophysica acta.

[10]  Baoan Chen,et al.  The changes of T lymphocytes and cytokines in ICR mice fed with Fe3O4 magnetic nanoparticles , 2011, International journal of nanomedicine.

[11]  M. Liao,et al.  Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. , 2007, International immunopharmacology.

[12]  Chia-Chi Wang,et al.  A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice , 2011, International journal of nanomedicine.

[13]  Mark A. Smith,et al.  Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance , 2006, Neuroscience Letters.

[14]  A. Dinda,et al.  Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress , 2010, International journal of nanomedicine.

[15]  K. Landfester,et al.  The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. , 2010, Biomaterials.

[16]  M. Taupitz,et al.  Contrast‐enhanced MR imaging of liver and spleen: First experience in humans with a new superparamagnetic iron oxide , 1994, Journal of magnetic resonance imaging : JMRI.

[17]  Yu Zhang,et al.  The effect of magnetic nanoparticles of Fe3O4 on immune function in normal ICR mice , 2010, International journal of nanomedicine.

[18]  P. Reimer,et al.  Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications , 2003, European Radiology.

[19]  L. Josephson,et al.  The effects of iron oxides on proton relaxivity. , 1988, Magnetic resonance imaging.

[20]  T. Mosmann,et al.  Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. , 1987, Journal of immunology.

[21]  Kyunghee Choi,et al.  Inflammatory responses may be induced by a single intratracheal instillation of iron nanoparticles in mice. , 2010, Toxicology.

[22]  Baoan Chen,et al.  Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice , 2010, International journal of nanomedicine.

[23]  Meng Wang,et al.  Comparative study of pulmonary responses to nano- and submicron-sized ferric oxide in rats. , 2008, Toxicology.

[24]  Alke Petri-Fink,et al.  Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells , 2011, Nanotoxicology.

[25]  D. Huber,et al.  Synthesis, properties, and applications of iron nanoparticles. , 2005, Small.

[26]  C. Marx,et al.  T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration--preliminary clinical experience with dynamic T1-weighted MR imaging. , 1998, Radiology.

[27]  Hiroyuki Honda,et al.  Medical application of functionalized magnetic nanoparticles. , 2005, Journal of bioscience and bioengineering.

[28]  A. Olukotun,et al.  Phase I clinical evaluation of a new iron oxide MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[29]  B. Hamm,et al.  Wertigkeit des leberspezifischen superparamagnetischen Kontrastmittels AMI-25 für die Detektion und Differentialdiagnose lebereigener Tumoren versus Metastasen , 1994 .